Dr. Giray (right), working with associates in Indonesia.
Our superior quality products are the result of 20+ years of research and development
Salmonics LLC was founded to commercialize products developed over the past 20 years by the R&D company Sea Run Holdings Inc. and to develop and market new reagents and products, such as fibronectin and serum, from blood harvested from farmed salmon. In collaboration with aquaculture companies providing the raw material, Salmonics creates a sustainable loop for a byproduct that would otherwise join the waste stream. Blood is collected using humane practices and processed under stringent conditions for purity. High quality proteins and reagents derived from salmon blood are utilized in regenerative medicine, cell proliferation, pain treatment and a variety of other research applications.
Salmonics LLC personnel and advisory board members combine expertise in a broad range of biomedical sciences, aquatic animal health and aquaculture, providing a productive interface between the research and commercial sectors.
Staff
Cem Giray, Ph.D.
CEO, President
download vcard
After studying microbiology and oceanography, Cem Giray chose to pursue a career in the aquatic private sector, working briefly as… read more
Veronica Achorn
Head of Operations
download vcard
Veronica is an experienced scientist with an affinity toward operations and business. She studied marine sciences at the University of Maine with a focus on… read more
Scientific Advisory Board
Evelyn S. Sawyer, Ph.D.
Dr. Sawyer has a diverse background which combines academic work in zoology with experience in the aquaculture industry. Dr. Sawyer earned a Ph.D in Zoology from the University of New Hampshire in 1974 while she was the biologist for the first salmon farm on the East Coast. Dr. Sawyer continued working with fish as a pathologist for the Sea Grant Program until she founded Sea Run. Dr. Sawyer guided Sea Run through the transition from salmon aquaculture to biotechnology and is a pioneer in the development of proteins, therapeutants and other reagents from salmon blood. She is an author on 12 patents and numerous publications.
Paul A. Janmey, Ph.D.
Dr. Janmey is a professor of physiology, physics and bioengineering at the Institute of Medicine and Engineering at the University of Pennsylvania. He received his Ph.D. in physical chemistry from the University of Wisconsin and was a research fellow at the Hematology-Oncology Unit at Massachusetts General Hospital. Dr. Janmey’s research interests include the interaction between cytoskeletal and extracellular matrix stiffness, effects of substrate mechanics on cell structure and function, phosphoinositide signaling for actin assembly, fibrin-based materials for wound healing, and intermediate filament assembly and mechanics. He was awarded the Humboldt Prize in 2007 for his research.
Salmonics featured as an up-and-coming innovator
Salmonics is featured as one of TechPlace’s up-and-coming innovators in the 2022 Fact Book: Doing Business in Maine by MaineBiz MaineBiz story by Fred J. Field, August 1, 2022 (page 78)
Salmonics highlighted in MaineBiz as a growing startup
“Room to grow: How Maine startups find physical space to scale up” Salmonics is highlighted in the Mainebiz story by Peter Van Allen, June 27, 2022 (page 14)
Salmonics launches the original Sea Block®
Salmonics LLC is pleased to announce the launch of the original Sea Block® — a high-performance non-mammalian blocking buffer derived from pure salmonid proteins. Sea Block® provides high sensitivity, improved signal to noise ratio, and low cross-reactivity, particularly with mammalian-origin samples. It is appropriate for use in western blotting and other immunohistochemistry systems. Sea…
